Raises FY25 combined adjusted R&D and SG&A expenses view to $1.784B-$2.184B from $1.2B-$1.3B.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta put volume heavy and directionally bearish
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- SRPT Earnings this Week: How Will it Perform?
- Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
- RBC sees Makary interview as potentially positive for biotech stocks